Skip to main content

Table 3 Results of preliminary stability studies

From: Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B

Description

Limits

2-8oC

40oC

  

0

3

6

12

1

3

6

Particle size (light microscopy)

≥ 60% of under 50 µm

S

-

S

S

NP

NP

NP

Shape (light microscopy)

elongated tubular structures

S

-

-

S

NP

NP

NP

pH

7±0.5

7,4

7,1

7,1

7,1

7,2

7,2

7,3

Appearance

Milky suspension

S

S

S

S

S

S

S

Free Ca2+ (atomic absorption)

<5 mM

<0,1

<0,1

NP

<0,1

-

<0,1

<0,3

Protein concentration (Lowry)

1,2±0,2 mg/mL

1,19

1,26

NP

1,27

1,19

1,2

1,26

Preservative (atomic absorption)

0.07-0.13 mg/mL

0.1

NP

NP

0,09

NP

NP

NP

Identity (SDS/PAGE)

two majority bands between 36 and 46 kDa and two minor between 70 and 85 kDa

P

P

NP

P

P

P

P

Microbial limit

Less than <102 aerobic bacteria or fungi by Pseudomonas aeruginosa m. Absence of Staphylococcus aureus, Escherichia coli and Salmonella

S

S

NP

NP

NP

NP

NP

Preservative

Microbial growth reduction <2 log at 14 days and no microbial growth increased from 14 to 28 days

S

S

NP

S

S

S

S

Potency ELISA(IgA)

IgA in saliva anti OMV > 250 UA

261.33

503

NS

882.17

NS

NS

NS

Potency ELISA(IgG)

IgG in serum anti OMV

S

S

S

S

S

S

S

  1. Legend: S, Satisfactory; NS, Not satisfactory; NP, Not planned; – , Not evaluated or planned; P, Positive